Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:vardenafil
|
| gptkbp:alternativeName |
vardenafil ODT
|
| gptkbp:ATCCode |
gptkb:G04BE09
|
| gptkbp:chemicalClass |
phosphodiesterase type 5 inhibitor
|
| gptkbp:contraindication |
nitrate medications
severe liver impairment |
| gptkbp:FDAApproved |
approved
|
| gptkbp:form |
orally disintegrating tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Staxyn
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bayer
GlaxoSmithKline |
| gptkbp:marketedIn |
gptkb:Canada
gptkb:United_States |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
nasal congestion dyspepsia flushing |
| gptkbp:usedFor |
erectile dysfunction
|
| gptkbp:bfsParent |
gptkb:vardenafil
|
| gptkbp:bfsLayer |
6
|